2 October 2019 - As outcry around drug prices rages, arguments continue to surface that limiting corporate revenues via price controls will have little impact on biopharmaceutical innovation. 

The latest salvo comes from academics at Rutgers Law School. In an article published by STAT, the authors claim that the industry grossly overstates the impact of price controls, likening the industry to Aesop’s boy who cried wolf.

“Big Pharma has cried Innovation Wolf every time Congress seeks to address its shenanigans. And the legislators keep coming to defend it. That has got to stop. It is past time for the industry to be called to account on using its get-out-of-jail-free innovation card to avoid reasonable legislation. As we get closer to the finish line of passing legislation addressing product hopping and other games, the cries about threats to innovation will grow louder and more urgent. But the industry’s history needs to be remembered. Consumers’ lives depend on it.”

Read Forbes article